• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

IBM partners to identify risk factors for Type I diabetes

August 18, 2017 By Sarah Faulkner

IBMIBM (NYSE:IBM) plans to develop and apply machine learning techniques to years of research data in the hopes of identifying factors that trigger the onset of Type I diabetes in children, with the support of JDRF.

Scientists at IBM are slated to assess three different data sets using machine learning algorithms to find patterns and factors that could one day help delay or prevent Type I diabetes.

“At JDRF, we are absolutely committed to seeing a world without Type I diabetes, and with this partnership, we’re adding some of the most advanced computing power in the world to our mission,” JDRF president & CEO Derek Rapp said in prepared remarks. “JDRF supports researchers all over the world, but never before have we been able to analyze their data comprehensively, in a way that can tell us why some children who are at risk get T1D and others do not. IBM’s analysis of the existing data could open the door to understanding the risk factors of T1D in a whole new way, and to one day finding a way to prevent T1D altogether.”

The group may eventually incorporate more complex data sets, they said, including microbiome and genomics data.

“Nearly 40,000 new cases of Type I diabetes will be diagnosed in the U.S. this year. And each new patient creates new records and new data points that, if leveraged, could provide additional understanding of the disease,” Jianying Hu, senior manager and program director at the Center for Computational Health, added. “The deep expertise our team has in artificial intelligence applied to healthcare data makes us uniquely positioned to help JDRF unlock the insights hidden in this massive data set and advance the field of precision medicine towards the prevention and management of diabetes.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2.

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: IBM, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS